Sexton, Rachel
https://orcid.org/0000-0002-0008-9629
Mayo Clinic
SWOG Statistical Center, Seattle, WA
Citations 2
P965: FOLLOW-UP ANALYSIS OF THE RANDOMIZED PHASE II TRIAL OF BORTEZOMIB, LENALIDOMIDE, DEXAMTHASONE WITH/WITHOUT ELOTUZUMAB FOR NEWLY DIAGNOSED, HIGH RISK MULTIPLE MYELOMA (SWOG-1211)
Hoering, Antje , Sexton, Rachel , Valent, Jason , Rosenzweig, M., Zonder, Jeff, Dhodapkar, M., Zimmerman, T., Voorhees, Peter M. , Durie, Brian, Richardson, PG, Usmani, Saad Z. , Ailawadhi, Sikander , Sexton, R., Lipe, Brea , Valent, Jason Neil , Rosenzweig, Michael , Callander, Natalie S. , Rajkumar, S. Vincent , Orlowski, Robert Z.
HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 855-856
SWOG 1211: A randomized phase I/II study of optimal induction therapy for newly diagnosed high-risk multiple myeloma (HRMM).
Usmani, Saad Zafar, Hoering, Antje , Sexton, Rachel , Shah, Jatin J., Fredette, Sandi, Durie, Brian G.M. , Zonder, Jeffrey A. , Dhodapkar, Madhav V. , Mahindra, Anuj, Zimmerman, Todd M., Richardson, Paul G. , Usmani, Saad Zafar, Ailawadhi, Sikander , Rajkumar, S. Vincent , Richardson, Paul Gerard Guy , Orlowski, Robert Z.
Journal of Clinical Oncology | January 3, 2019 | Volume: 32 | Issue: 15_suppl | Pages: TPS8624-TPS8624